Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?
Intellia Therapeutics Ownership Summary
Intellia Therapeutics is owned by 3.68% institutional investors, 4.96% insiders, and 91.36% retail investors. Ark investment management is the largest institutional shareholder, holding 12.41% of NTLA shares. ARK Innovation ETF is the top mutual fund, with 8.90% of its assets in Intellia Therapeutics shares.
NTLA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Intellia Therapeutics | 3.68% | 4.96% | 91.36% |
| Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
| Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Ark investment management | 12.54M | 12.41% | $146.17M |
| Blackrock funding, inc. /de | 10.86M | 10.75% | $126.60M |
| Vanguard group | 10.19M | 10.09% | $118.82M |
| Blackrock | 9.60M | 10.05% | $214.79M |
| State street | 4.36M | 4.57% | $97.64M |
| Regeneron pharmaceuticals | 3.70M | 3.67% | $43.18M |
| Nikko asset management americas | 2.99M | 2.96% | $34.89M |
| Sumitomo mitsui trust | 2.99M | 2.96% | $34.89M |
| Morgan stanley | 2.34M | 2.45% | $52.32M |
| Geode capital management | 2.39M | 2.37% | $27.86M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Regeneron pharmaceuticals | 3.70M | 3.94% | $43.18M |
| Discovery value fund | 561.56K | 3.76% | $6.55M |
| Contrarius investment management | 1.92M | 2.68% | $42.87M |
| Himension capital (singapore) pte. | 1.03M | 1.63% | $23.05M |
| Ark investment management | 12.54M | 1.22% | $146.17M |
| Casdin capital | 2.00M | 1.16% | $14.22M |
| Orchard capital management | 170.01K | 1.15% | $3.80M |
| Sphera funds management | 466.08K | 0.98% | $5.43M |
| Second line capital | 131.12K | 0.41% | $1.53M |
| Nikko asset management americas | 2.99M | 0.38% | $34.89M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Regeneron pharmaceuticals | 3.70M | 3.94% | 3.70M |
| Balyasny asset management | 2.31M | 0.04% | 1.56M |
| Ubs group | 1.74M | 0.00% | 1.46M |
| Blackrock funding, inc. /de | 10.86M | 0.00% | 1.08M |
| Voloridge investment management | 1.53M | 0.06% | 1.06M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Deep track capital, lp | - | - | -4.95M |
| Capital investors | - | - | -3.78M |
| Federated hermes | 3.85K | 0.00% | -2.74M |
| Alliancebernstein | 265.32K | 0.00% | -1.93M |
| Pictet asset management sa | - | - | -1.39M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Regeneron pharmaceuticals | 3.70M | 3.94% | 3.70M | $43.18M |
| Raymond james financial | 411.08K | 0.00% | 411.08K | $4.79M |
| Aptus capital advisors | 139.28K | 0.02% | 139.28K | $1.62M |
| Second line capital | 131.12K | 0.41% | 131.12K | $1.53M |
| Aqr capital management | 35.76K | 0.00% | 35.76K | $416.93K |
Sold Out
| Holder | Change |
|---|---|
| Dinuzzo private wealth | -1.00 |
| Global financial private client | -1.00 |
| Jfs wealth advisors | -2.00 |
| Richard w. paul & associates | -2.00 |
| First pacific financial | -2.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 6 | -98.05% | 3,804,135 | -96.17% | 3 | 0.04% | 3 | -98.41% | 1 | -98.55% |
| Dec 31, 2024 | 286 | -2.39% | 92,252,291 | -1.01% | 91 | 1.07% | 178 | 17.11% | 61 | -27.38% |
| Sep 30, 2024 | 290 | -5.54% | 93,104,860 | 3.35% | 92 | 1.07% | 150 | -7.41% | 84 | -4.55% |
| Jun 30, 2024 | 302 | 0.67% | 90,028,919 | -0.69% | 94 | 1.05% | 160 | 5.26% | 86 | -2.27% |
| Mar 31, 2024 | 300 | -2.28% | 90,656,601 | 6.41% | 94 | 1.03% | 152 | -11.11% | 88 | 10.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ARK Innovation ETF | 9.55M | 8.90% | 907.21K |
| ARK Disruptive Innovation Full Composite | 8.70M | 8.41% | 81.62K |
| American Funds SMALLCAP World A | 3.78M | 3.65% | 3.78M |
| Vanguard Total Stock Mkt Idx Inv | 3.24M | 3.12% | - |
| Vanguard US Total Market Shares ETF | 3.17M | 3.06% | 299.88K |
| ARK Genomic Revolution | 3.10M | 2.99% | 235.36K |
| ARK Genomic Revolution ETF | 2.85M | 2.75% | -17.09K |
| Vanguard Small Cap Index | 2.53M | 2.44% | -38.83K |
| iShares Russell 2000 ETF | 2.43M | 2.27% | -46.20K |
| Nikko AM ARK Disruptive Innovation A USD | 1.76M | 1.70% | -68.46K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 23, 2025 | Dulac Edward J III | EVP, Chief Financial Officer | Sell | $104.62K |
| Jul 01, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | $10.04K |
| Jul 02, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | $24.90K |
| Jul 01, 2025 | GOODMAN JESSE | - | Sell | $14.28K |
| Jun 30, 2025 | GOODMAN JESSE | - | Sell | $14.79K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 4 |
| 2025 Q2 | - | 2 |
| 2025 Q1 | - | 11 |
| 2024 Q4 | - | 1 |
| 2024 Q3 | - | 1 |
NTLA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools